EGFR and glioblastoma: GBM is further distinguished by key molecular alterations, including epidermal growth factor receptor (EGFR) amplification, telomerase reverse transcriptase (TERT) promoter mutations, and distinct chromosomal abnormalities.2,3 These features contribute to the highly invasive nature and resistance of tumors to conventional therapies.